Article Text

Download PDFPDF
Polypill strategy at the heart of cardiovascular secondary prevention

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests BI and VF have no personal conflicts of interest to declare. JMC has received speaker fees and travel support from Ferrer. The CNIC is a non-profit public institution that receives royalties for the sales of a polypill (Trinomia) composed of aspirin, ramipril and atorvastatin, but no CNIC researcher has direct interests or receives any personal benefits.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles